Sitryx Therapeutics
http://www.sitryx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sitryx Therapeutics
Start-Up Quarterly Statistics, Q1 2020
A review of biopharma start-up dealmaking and financing activity from January through March 2020, based on data from Biomedtracker.
Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Manipulating Metabolism: Lilly Links With UK Biotech Sitryx
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
Lilly Opens Its Wallet For Early Immunology Tie-Up With ImmuNext
Lilly is prepared to splash over $600m on an early development deal with ImmuNext on an immunometabolism target which ties the companies together for three years while an antibody is being developed.
Company Information
- Industry
- Biotechnology